The CASPIAN study evaluated the efficacy and safety of durvalumab plus tremelimumab and platinum-etoposide extensive-stage SCLC. touchONCOLOGY spoke to Niels Reinmuth (Munich, Germany) to discuss the characteristics of long-term survivors in the CASPIAN study.
Clinical Trial Identification: NCT03043872
- What did the CASPIAN study teach us about the efficacy and safety of durvalumab plus tremelimumab and platinum-etoposide extensive-stage SCLC? 00:18-01:58
- What was the rationale for your current analysis of CASPIAN data? 01:58-02:42
- What were the findings of this study and what are their clinical implications? 02:42-03:03
- What questions remain unanswered and what future studies are planned? 03:03-04:04
Speaker Disclosure: Niels Reinmuth is a Speaker’s Bureau participant with: Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Hoffmann-La Roche, MSD, Merck, Pfizer, and Takeda.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the European Lung Cancer Summit 2022
Share this Video
Related Videos In Lung Cancer
Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer
First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]
Charles Swanton, ESMO 2022: Mechanism of action and an actionable inflammatory axis for air pollution may induce NSCLC in never-smokers
The mechanistic basis for non-small cell lung cancer (NSCLC) initiation in never smokers is unknown. The air pollutant, particulate matter, is known to be associated with the risk of NSCLC, however a direct cause and mechanism remains difficult to achieve. Prof. Charles Swanton (Francis Crick Institute, London, UK) joins touchONCOLOGY to discuss his study into […]
Catherine A. Shu, ASCO 2022: Updated results from the CHRYSALIS-2 of amivantamab and lazertinib in patients with advanced NSCLC
Dr Catherine Shu (Columbia University Irving Medical Center, New York, NY, USA) discusses the findings of the CHRYSALIS-2 study, which supports the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer (NSCLC) and represents a chemotherapy-free regimen. The abstract ‘Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!